Valproate and lamotrigine in pediatric patients with refractory epilepsy: after the first year

Area of Science:

• Pediatric Neurology
• Pharmacology

Background:

• Refractory epilepsy in children poses significant treatment challenges.
• Limited data exists on the long-term efficacy and safety of combined antiepileptic drug (AED) therapy in pediatric populations.

Purpose of the Study:

• To evaluate the pharmacologic properties, efficacy, and safety of lamotrigine in combination with valproate/divalproex sodium in pediatric patients with refractory epilepsy.
• To assess the long-term outcomes, including seizure control and adverse events, over an extended follow-up period.

Main Methods:

• A cohort of 51 pediatric patients (4-16 years) with refractory epilepsy received lamotrigine combined with valproate/divalproex sodium.
• Patients were monitored for seizure frequency, type (generalized or focal), and adverse events over two years.
• Lamotrigine was introduced gradually to minimize adverse effects.

Main Results:

• The combination therapy demonstrated significant efficacy, with 76.5% of patients achieving therapeutic benefit in the first year and 70.6% in the second year.
• A notable reduction in drop attacks was observed in 88.5% of affected patients.
• Rash was the most common adverse effect, leading to discontinuation in 7.8% of patients.

Conclusions:

• Lamotrigine combined with valproate/divalproex sodium is an effective treatment option for pediatric refractory epilepsy.
• A slower titration of lamotrigine improves tolerability, adherence, and quality of life.
• Sustained therapeutic efficacy can be achieved with optimized dosing strategies, even beyond the first year of treatment.